Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
35.48
+0.83 (2.40%)
Mar 6, 2026, 4:00 PM EST - Market closed
Stoke Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 205.63 | 36.56 | 8.78 | 12.41 | - | - | |
| Revenue Growth (YoY) | 1128.17% | 316.34% | -29.22% | - | - | - | |
| Gross Profit | 205.63 | 36.56 | 8.78 | 12.41 | - | - | |
| Selling, General & Admin | 58.79 | 48.79 | 41.32 | 38.92 | 31.9 | 20.85 | |
| Research & Development | 119.65 | 89.13 | 82.23 | 77.84 | 54.17 | 32.2 | |
| Operating Expenses | 178.44 | 137.93 | 123.55 | 116.76 | 86.07 | 53.04 | |
| Operating Income | 27.2 | -101.37 | -114.77 | -104.36 | -86.07 | -53.04 | |
| Interest & Investment Income | 13.11 | 12.64 | 9.91 | 3.12 | 0.12 | 0.7 | |
| Other Non Operating Income (Expenses) | 0.26 | -0.25 | 0.17 | 0.17 | 0.14 | 0.1 | |
| Pretax Income | 40.57 | -88.98 | -104.7 | -101.07 | -85.81 | -52.24 | |
| Net Income | 40.57 | -88.98 | -104.7 | -101.07 | -85.81 | -52.24 | |
| Net Income to Common | 40.57 | -88.98 | -104.7 | -101.07 | -85.81 | -52.24 | |
| Shares Outstanding (Basic) | 58 | 54 | 44 | 39 | 37 | 33 | |
| Shares Outstanding (Diluted) | 60 | 54 | 44 | 39 | 37 | 33 | |
| Shares Change (YoY) | 16.83% | 22.76% | 13.11% | 5.87% | 9.71% | 86.34% | |
| EPS (Basic) | 0.70 | -1.65 | -2.38 | -2.60 | -2.34 | -1.56 | |
| EPS (Diluted) | 0.68 | -1.65 | -2.38 | -2.60 | -2.34 | -1.56 | |
| Free Cash Flow | 52.37 | -87.05 | -82.68 | -35.83 | -68.11 | -43.27 | |
| Free Cash Flow Per Share | 0.88 | -1.61 | -1.88 | -0.92 | -1.85 | -1.29 | |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | - | - | |
| Operating Margin | 13.23% | -277.31% | -1307.21% | -841.24% | - | - | |
| Profit Margin | 19.73% | -243.42% | -1192.47% | -814.73% | - | - | |
| Free Cash Flow Margin | 25.47% | -238.15% | -941.72% | -288.82% | - | - | |
| EBITDA | 29.09 | -99.2 | -112.3 | -102.81 | -85.09 | -52.16 | |
| EBITDA Margin | 14.14% | -271.36% | - | - | - | - | |
| D&A For EBITDA | 1.89 | 2.18 | 2.47 | 1.55 | 0.97 | 0.89 | |
| EBIT | 27.2 | -101.37 | -114.77 | -104.36 | -86.07 | -53.04 | |
| EBIT Margin | 13.23% | -277.31% | - | - | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.